Airfinity has launched two new products, ID-Vx and ID-Tx. These new solutions combine to provide a holistic overview of all vaccine and treatment (including prophylactics) developments within the infectious disease space*. Candidates and changes to the landscape, clinical trials, new approvals, new deals, media and KOL discussions are all covered in a monthly report along with a topical deep dive.
What is ID-Vx?
ID-Vx provides a full, top-line overview of the vaccine development landscape across infectious diseases (excluding COVID-19, RSV and Influenza). We track ~1000 candidates including pre-clinical and clinical candidates, across ~80 infectious diseases.
What is ID-Tx?
ID-Tx provides a full, top-line overview of the prophylactic and therapeutic development landscape across infectious diseases (excluding COVID-19, RSV and Influenza). We track ~850 candidates including pre-clinical and clinical candidates, across ~100 infectious diseases.
Both ID-Vx and ID-Tx provides a monthly report outlining:
→ An overview of candidates in development and changes to the candidate landscape
→ Clinical trial overviews including new locations and announced timelines of completion
→ New approvals
→ New deals (co-development, licensing, partnership, acquisition)
→ Media and Press Release overviews
→ KOL social media discussions
→ A deep dive of interest
What is the difference between ID-Tx and ID-Vx, and Science360?
Unlike ID-Vx and ID-Tx, which provide a high-level overview of the entire infectious disease landscape and developments, Science360 is Airfinity’s premium offering. Providing deeper analytics, tool building and modelling for a specific infectious disease.
Airfinity already provides full Science360 offerings for COVID-19, influenza and RSV but is able to build a Science360 offering for any infectious disease area of interest. A Science360 product covers all data within the ID-Vx and ID-Tx products but also includes conference coverage, publications, efficacy and safety results, epidemiology and other deeper analytics, tools, predictive models and forecasts.
To request a sample report and analysis for Pneumococcal Science360, get in touch here.